However, e.g. islet-specific antigen therapy alone has been disappointing in trials with type 1 diabetes patients and it has been suggested that antigen therapy must be combined with a Treg-inducing agent such as low-dose IL-2. The gene discussed is IL2; the disease is type 1 diabetes mellitus.